title: [Use of lymphotropic therapy in the multimodality treatment of patients with pulmonary tuberculosis and comorbidity].
abstract: Regional lymphotropic therapy involving 10% isoniazid administration was included into multimodality treatment in 250 patients with pulmonary tuberculosis and comorbidity. The findings have indicated that the lymphotropic therapy during the use of rifampicin, streptomycin, ethambutol enhances the efficiency of chemotherapy in different forms of pulmonary tuberculosis, including the latter concurrent with hepatic lesion or diabetes mellitus. Lymphotropic therapy is particularly beneficial to patients with poor drug tolerability. The use of lymphotropic isoniazid in the multimodality treatment of pulmonary tuberculosis leads to the earlier disappearance of the symptoms of tuberculous intoxication (by 1-1.5 months) in 80-92% of the patients, to abacillation in the same periods, to the increased frequency of decay cavity closure by an average of 15% as compared to the conventional treatment, and, in most cases, to the normalization of the biochemical parameters of hepatic function.
authors.forename: A M
authors.initials: AM
authors.lastname: Ubaĭdullaev
authors.forename: V G
authors.initials: VG
authors.lastname: Belotserkovets
mesh_terms: D000284:Administration, Oral; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007272:Injections, Intralymphatic; D007273:Injections, Intramuscular; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007538:Isoniazid / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D008107:Liver Diseases / Q000150:complications*; D008208:Lymphatic System / Q000187:drug effects*; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D013307:Streptomycin / Q000008:administration & dosage / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D007004:Hypoglycemic Agents; D007328:Insulin; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin